SERA
Sera Prognostics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Sera Prognostics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Mar 18 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 18 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; no measured co-movers for Sera Prognostics, Inc..
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; no measured co-movers for Sera Prognostics, Inc..
Sera Prognostics, Inc.
1.97
+0.04 · +2.07%
Linked news
NewsTall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Baker Bros. | $10.0M | 32.23% | 0.00% |
| Whetstone Capital | $6.0M | 19.39% | 0.00% |
| Standard Life Aberdeen | $5.0M | 16.14% | +7.95% |
| Vivo Capital | $3.0M | 9.68% | 0.00% |
| Vanguardindex-like | $2.4M | 7.61% | +7.78% |
| Manager | Value | % base | |
|---|---|---|---|
| Baker Bros. | $10.0M | 32.23% | 0.00% |
| Whetstone Capital | $6.0M | 19.39% | 0.00% |
| Standard Life Aberdeen | $5.0M | 16.14% | +7.95% |
| Vivo Capital | $3.0M | 9.68% | 0.00% |
| Vanguardindex-like | $2.4M | 7.61% | +7.78% |
Bull1
Bear1
Expected move
No implied move.